Eris Lifesciences (ERIS.NS) Dividend: History, Dates & Yield - 2025
Dividend History
Eris Lifesciences announced a annually dividend of ₹7.35 per ordinary share, payable on 2025-03-09, with an ex-dividend date of 2025-02-13. Eris Lifesciences typically pays dividends one times a yearFor 2025, the total annual dividend was ₹7.35.
Find details on Eris Lifesciences's dividend performance with a comprehensive history of past and upcoming payments.
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2025-02-13 | ₹7.35 | annually | 2025-03-09 |
2022-08-11 | ₹7.35 | annually | 2022-09-04 |
2021-08-05 | ₹6.01 | annually | 2021-08-28 |
2020-08-13 | ₹5.50 | annually | 2020-09-03 |
2020-03-19 | ₹2.87 | annually | 2020-04-10 |
Dividend Increase
. In comparison, Caplin Point Laboratories has seen an average growth rate of 18.12% over the past five years and J. B. Chemicals & Pharmaceuticals's growth rate was 39.19%.
By comparing Eris Lifesciences's dividend growth to other companies, investors can gain insight into how consistent its dividend strategy is and what that means for future payouts. However, dividend growth is just one factor to consider. Investors should also evaluate other metrics, such as earnings growth, payout ratio, and overall financial health, to get a full picture of Walmart's dividend sustainability and potential.
Dividend Yield
Eris Lifesciences's current trailing twelve-month (TTM) dividend yield is 0.58%. Over the last 12 months, Eris Lifesciences has maintained this yield, but how does it compare to similar stocks? For example, Caplin Point Laboratories offers a yield of 0.24%, while J. B. Chemicals & Pharmaceuticals provides a yield of 0.94%. Comparing similar stocks can help investors assess Eris Lifesciences's yield and make more informed decisions.
Company | Dividend Yield | Annual Dividend | Stock Price |
---|---|---|---|
Eris Lifesciences (ERIS.NS) | 0.58% | ₹7.35 | ₹1275.85 |
Caplin Point Laboratories (CAPLIPOINT.NS) | 0.24% | ₹5 | ₹2052.9 |
J. B. Chemicals & Pharmaceuticals (JBCHEPHARM.NS) | 0.94% | ₹12.25 | ₹1621.15 |
Dividend Yield Calculator
Interested in purchasing Eris Lifesciences stock? Use our calculator to estimate your expected dividend yield and see how Walmart's consistent payouts could contribute to your long-term investment goals. Understanding your potential returns can help you make an informed decision.
Payout Ratio
Eris Lifesciences has a payout ratio of 0.00%. In comparison, Caplin Point Laboratories has a payout ratio of 0.00%, while Alkem Laboratories's payout ratio is 0.00%.
It's important to note that the payout ratio is just one of many metrics investors use to assess a company's dividend sustainability and growth potential. It should be considered alongside other financial indicators such as earnings, cash flow, and debt levels to gain a complete picture of the company's financial health.
About Eris Lifesciences
Frequently Asked Question
Other factors to consider when evaluating Eris Lifesciences as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Eris Lifesciences stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Eris Lifesciences's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Eris Lifesciences publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Eris Lifesciences distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Eris Lifesciences are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Eris Lifesciences sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Eris Lifesciences distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Eris Lifesciences declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Eris Lifesciences's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Eris Lifesciences's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.